| Autor: |
Beyer, Susanne, Müller, Lena, Mitter, Sophie, Keilmann, Lucia, Meister, Sarah, Buschmann, Christina, Kraus, Fabian, Topalov, Nicole E., Czogalla, Bastian, Trillsch, Fabian, Burges, Alexander, Mahner, Sven, Schmoeckel, Elisa, Löb, Sanja, Corradini, Stefanie, Kessler, Mirjana, Jeschke, Udo, Kolben, Thomas |
| Předmět: |
|
| Zdroj: |
Journal of Cancer Research & Clinical Oncology; Jul2023, Vol. 149 Issue 8, p4293-4303, 11p |
| Abstrakt: |
Purpose: Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. Methods: 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). Results: High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival. Conclusion: Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink